Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    18375893 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer
Condition: Ovarian Cancer
Interventions: Drug: Pembrolizumab;   Drug: Carboplatin;   Drug: Paclitaxel
2 Unknown  Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment
Condition: Metastatic Breast Cancer
Interventions: Drug: Paclitaxel and Sorafenib;   Drug: Paclitaxel

Indicates status has not been verified in more than two years